Cargando…

Influence of Race and Sex on Thrombogenicity in a Large Cohort of Coronary Artery Disease Patients

BACKGROUND: It is uncertain whether sex and race affect thrombogenicity in patients with coronary artery disease. We evaluated the effects of sex and race on thrombogenicity in patients with coronary artery disease treated with aspirin. METHODS AND RESULTS: Patients on aspirin therapy for 1 week or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lev, Eli I., Bliden, Kevin P., Jeong, Young‐Hoon, Pandya, Shachi, Kang, Kelly, Franzese, Christopher, Tantry, Udaya S., Gurbel, Paul A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323822/ https://www.ncbi.nlm.nih.gov/pubmed/25332180 http://dx.doi.org/10.1161/JAHA.114.001167

Ejemplares similares

Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations
por: Chaudhary, Rahul, et al.
Publicado: (2020)

Further evidence for the use of aspirin in COVID-19
por: Tantry, Udaya S., et al.
Publicado: (2022)

Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction
por: Kang, Min Gyu, et al.
Publicado: (2021)

Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences
por: Kim, Hyun Kuk, et al.
Publicado: (2021)

IS THERE A ROLE FOR α1-ANTITRYPSIN IN COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

AGE-BASED RISK FACTORS FOR SYMPTOMATIC COVID-19 IN THE MINORITY POPULATION
por: Gurbel, Paul A., et al.
Publicado: (2021)

Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent
por: Tantry, Udaya S, et al.
Publicado: (2021)

IS LOW DOSE ASPIRIN EFFECTIVE IN REDUCING IN-HOSPITAL CLINICAL OUTCOMES IN PATIENTS WITH COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

Personalized antiplatelet therapy: state of the art
por: Gurbel, Paul A, et al.
Publicado: (2012)

Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing
por: Jeong, Young-Hoon, et al.
Publicado: (2019)

Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention
por: Jeong, Young-Hoon, et al.
Publicado: (2012)

In Vitro Evidence for the Role of Cytokine Storm in the Generation of Stent Thrombosis in COVID-19 Patients
por: Gurbel, Paul A., et al.
Publicado: (2022)

Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial
por: Park, Hyun-Woong, et al.
Publicado: (2021)

A Novel Large Animal Model of Thrombogenic Coronary Microembolization
por: Bikou, Olympia, et al.
Publicado: (2019)

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
por: Gurbel, Paul A., et al.
Publicado: (2018)

Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus
por: Jung, Jung Hwa, et al.
Publicado: (2015)

Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can “Thrombin Pathway” Be a New Target for Therapy?
por: Kim, Hyun Kuk, et al.
Publicado: (2020)

Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population
por: Gurbel, Paul A., et al.
Publicado: (2021)

Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes
por: Usman, Abira, et al.
Publicado: (2022)

First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19
por: Tantry, Udaya S, et al.
Publicado: (2021)

Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2012)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
por: Gurbel, Paul A, et al.
Publicado: (2010)

International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests
por: Gurbel, Paul A., et al.
Publicado: (2021)

The involvement of multiple thrombogenic and atherogenic markers in premature coronary artery disease
por: Mansur, Antonio P., et al.
Publicado: (2013)

State of the art: Oral antiplatelet therapy
por: Gurbel, Paul A, et al.
Publicado: (2016)

High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells
por: Grześk, Grzegorz, et al.
Publicado: (2013)

Can an Old Ally Defeat a New Enemy?
por: Gurbel, Paul A., et al.
Publicado: (2020)

Hyperdense large artery sign in meningitis: A marker of ominous thrombogenic potential of pneumococcus?
por: Mojumder, Deb Kumar, et al.
Publicado: (2014)

Cryopreservation moderates the thrombogenicity of arterial allografts during storage
por: Hidi, László, et al.
Publicado: (2021)

Anti-Inflammatory and Anti-Thrombogenic Properties of Arterial Elastic Laminae
por: Goldman, Jeremy, et al.
Publicado: (2023)

PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study
por: Kuliopulos, Athan, et al.
Publicado: (2020)

Device Thrombogenicity Emulation: An In Silico Predictor of In Vitro and In Vivo Ventricular Assist Device Thrombogenicity
por: Chiu, Wei Che, et al.
Publicado: (2019)

Mechanical Extraction of a Massive Intracoronary Thrombus from the Super-Dominant Right Coronary Artery in Thrombogenic Lung Cancer Patient
por: Kim, Dong-Kie, et al.
Publicado: (2015)

Intracoronary Thrombogenicity in Patients with Vasospastic Angina: An Observation Using Coronary Angioscopy
por: Teragawa, Hiroki, et al.
Publicado: (2021)

Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
por: Kang, Min Gyu, et al.
Publicado: (2022)

The Influence of Sex, Age, and Race on Coronary Artery Disease: A Narrative Review
por: Lima Dos Santos, Célia C, et al.
Publicado: (2023)

Antiplatelet Therapy Combinations and Thrombogenicity in Patients with Non-Valvular Atrial Fibrillation
por: Park, Yongwhi, et al.
Publicado: (2017)

Nanomedicine for the reduction of the thrombogenicity of stent coatings
por: Karagkiozaki, Varvara C, et al.
Publicado: (2010)

Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation
por: Berezin, Alexander E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vgmlv2eq80d85t4f70t0skl1ah